Evaluation of short- and long-term response to treatment in GIMEMA protocol for Acute Myeloid Leukaemia
by I. Ardoino, F. Ambrogi, S. Iacobelli, P. Boracchi, G. Manikis, M.G. Kounelakis, M. Zervakis, P.J.G. Lisboa, P. Fazi, M. Vignetti, E.M. Biganzoli, A. Starita
International Journal of Biomedical Engineering and Technology (IJBET), Vol. 3, No. 3/4, 2010

Abstract: Acute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.

Online publication date: Tue, 13-Apr-2010

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biomedical Engineering and Technology (IJBET):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com